Trials / Completed
CompletedNCT02013804
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open label, first-in-human dose-escalation study of MEDI0680 (AMP-514) to evaluate the safety, tolerability, PK, immunogenicity (IM), and antitumor activity in adult subjects with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI0680 (AMP-514) | Study has planned dose escalation cohorts |
Timeline
- Start date
- 2013-12-19
- Primary completion
- 2017-05-18
- Completion
- 2017-05-18
- First posted
- 2013-12-17
- Last updated
- 2017-10-06
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02013804. Inclusion in this directory is not an endorsement.